Edition:
India

OncoMed Pharmaceuticals Inc (OMED.OQ)

OMED.OQ on NASDAQ Stock Exchange Global Select Market

4.95USD
22 Nov 2017
Change (% chg)

$0.38 (+8.32%)
Prev Close
$4.57
Open
$4.57
Day's High
$4.98
Day's Low
$4.57
Volume
38,425
Avg. Vol
44,980
52-wk High
$10.86
52-wk Low
$2.93

Chart for

About

OncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include... (more)

Overall

Beta: 2.74
Market Cap(Mil.): $164.07
Shares Outstanding(Mil.): 37.63
Dividend: --
Yield (%): --

Financials

BRIEF-Oncomed posts Q3 loss per share $0.28

* Oncomed announces third quarter 2017 financial results and operational highlights

03 Nov 2017

BRIEF-OncoMed CEO Paul Hastings to take medical leave of absence

* OncoMed chairman and CEO, Paul Hastings, to take medical leave of absence

19 Sep 2017

BRIEF-OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial

* OncoMed doses first patient with GITRL-Fc in phase 1a clinical trial Source text for Eikon: Further company coverage:

13 Sep 2017

BRIEF-Oncomed Pharmaceuticals Q2 loss per share $0.40

* Q2 revenue $6.2 million versus $6.7 million Source text for Eikon: Further company coverage:

03 Aug 2017

Competitors

Earnings vs. Estimates